{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:25:09Z","timestamp":1792959909548,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BRIDGE21XX1"],"award-info":[{"award-number":["BRIDGE21XX1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CUTT13A1"],"award-info":[{"award-number":["CUTT13A1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:31:14Z","timestamp":1708561874000},"page":"664-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Hermann","family":"Bihler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Sivachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4531-6952","authenticated-orcid":false,"given":"Priyanka","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita Thakerar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Musisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1718-9794","authenticated-orcid":false,"given":"Andr\u00e9","family":"LaPan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand E.","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7534-3087","authenticated-orcid":false,"given":"Joshua","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah R.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-3746","authenticated-orcid":false,"given":"Amalia S.","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6854","authenticated-orcid":false,"given":"Karen S.","family":"Raraigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-8590","authenticated-orcid":false,"given":"Garry R.","family":"Cutting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Skach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-4455","authenticated-orcid":false,"given":"Philip J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-9789","authenticated-orcid":false,"given":"Martin","family":"Mense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcf.2024.02.006_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2013.12.008","article-title":"Annotating DNA variants is the next major goal for human genetics","volume":"94","author":"Cutting","year":"2014","journal-title":"Am J Hum Genet"},{"issue":"10290","key":"10.1016\/j.jcf.2024.02.006_bib0003","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic Fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jcf.2024.02.006_bib0004","article-title":"Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences","volume":"03","author":"Ideozu","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jcf.2024.02.006_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.02.006_bib0006","unstructured":"FDA. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217660s000lbl.pdf (revised 4\/2023)."},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.006_bib0008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Bio Cell"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.006_bib0009","first-page":"L405","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium","volume":"266","author":"Sheppard","year":"1994","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.006_bib0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.str.2016.03.004","article-title":"Manipulation of subunit stoichiometry in heteromeric membrane proteins","volume":"24","author":"Morales-Perez","year":"2016","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.006_bib0011","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1083\/jcb.121.5.1031","article-title":"Glycosylphosphatidylinositol-anchored proteins are preferentially targeted to the basolateral surface in Fischer rat thyroid epithelial cells","volume":"121","author":"Zurzolo","year":"1993","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jcf.2024.02.006_bib0012","unstructured":"Riordan J.R., Gentzsch M., https:\/\/cftrantibodies.web.unc.edu\/."},{"key":"10.1016\/j.jcf.2024.02.006_bib0013","series-title":"R: a language and environment for statistical computing","author":"Core Team","year":"2022"},{"issue":"44","key":"10.1016\/j.jcf.2024.02.006_bib0014","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX770","volume":"106","author":"Van Goor","year":"2009","journal-title":"PNAS"},{"issue":"46","key":"10.1016\/j.jcf.2024.02.006_bib0015","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.jcf.2024.02.006_bib0016","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"issue":"31","key":"10.1016\/j.jcf.2024.02.006_bib0017","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","article-title":"C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis","volume":"274","author":"Haardt","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2024.02.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.02.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.006_bib0020","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.ajhg.2018.04.003","article-title":"Functional assays are essential for interpretation of missense variants associated with variable expressivity","volume":"102","author":"Raraigh","year":"2018","journal-title":"Am J Hum Gen"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.006_bib0021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/jpm11050418","article-title":"Fertility, pregnancy and lactation considerations for women with CF in the CFTR modulator era","volume":"11","author":"Jain","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.006_bib0022","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcf.2020.07.003","article-title":"CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation","volume":"20","author":"Phuan","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2015.02.002","article-title":"Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: importance of functional studies to establish disease liability of mutations","volume":"15","author":"Ramalho","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.02.006_bib0024","first-page":"625","article-title":"Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention","volume":"16","author":"Molinski","year":"2014","journal-title":"Gen in Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.006_bib0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jcf.2022.04.019","article-title":"Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants","volume":"21","author":"Raraigh","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.02.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009100","article-title":"Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies","volume":"16","author":"Joynt","year":"2020","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.006_bib0027","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ajhg.2017.04.001","article-title":"Systematic computational identification of variants that activate exonic and intronic cryptic splice sites","volume":"100","author":"Lee","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.006_bib0028","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6446","key":"10.1016\/j.jcf.2024.02.006_bib0029","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2024.02.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102548","article-title":"Structure-based drug design with geometric deep learning","volume":"79","author":"Isert","year":"2023","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.jcf.2024.02.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(23)01216-X","article-title":"Beyond SION-638: a novel series of highly potent stabilizers of the first nucleotide binding domain enables full correction of \u0394F508-CFTR in a dual combination with Sionna CFTR modulators, providing a path to wild-type function","volume":"22","author":"Hurlbut","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.006_bib0033","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"14","key":"10.1016\/j.jcf.2024.02.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.006_bib0036","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.006_bib0037","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/cts.12927","article-title":"G970R-CFTR mutation (c.2908G>C) results predominantly in a splicing defect","volume":"14","author":"Fidler","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"17","key":"10.1016\/j.jcf.2024.02.006_bib0038","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jcf.2024.02.006_bib0039","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"13","key":"10.1016\/j.jcf.2024.02.006_bib0041","doi-asserted-by":"crossref","first-page":"e99385","DOI":"10.1172\/jci.insight.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.006_bib0042","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Sermet-Gaudelus I. Might brushed nasal cells be a surrogate for CFTR modulator clinical response?","volume":"199","author":"Pranke","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.02.006_bib0043","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.006_bib0044","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:08:43Z","timestamp":1783019323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000213"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}